Mr. Michal Efraty reports

NEUROTHERA LABS' CLINIQUANTUM REPORTS SUCCESSFUL QUANTUM-ENABLED ANALYSIS OF BILLIONS OF GENE COMBINATIONS USING REAL-WORLD CLINICAL DATA ON AN S&P 500 COMPANY'S QUANTUM ARCHITECTURE

Neurothera Labs Inc. majority-owned subsidiary, CliniQuantum Ltd., has released its graphics-processing-unit-accelerated (GPU) quantum-simulation platform. It has achieved an approximately 16.8-fold computational acceleration using a single machine with 64 cores (x86_64) and a single Nvidia T4 Tensor Core GPU compared with the same 64-vCPU machine with only central processing unit (CPU) implementation.

The evaluation used a real clinical gene-expression dataset comprising 11 patients and 3,531 gene-expression features, representing a challenging high-dimensional setting in which the number of biological variables greatly exceeds the number of patients.

The algorithm operated by CliniQuantum searched for correlated three-gene configurations across the dataset. The 3,531 genes generated 7,331,162,245 possible three-gene combinations. Using a predefined minimum correlation threshold, the algorithm identified approximately 22.2 million correlated gene triplets.

The analysis required approximately 8.4 hours using 64 vCPUs (virtual CPU), compared with approximately 0.5 hour when accelerated using a single Nvidia T4 GPU, while producing the same qualifying gene-triplet results.

The benchmark was conducted on an AWS g4dn.16xlarge EC2 machine using an IBM Qiskit Aer GPU-based quantum simulation, with a Nvidia T4 Tensor Core GPU. The benchmark was designed to evaluate computational performance and did not evaluate or establish the clinical validity, predictive value, or potential utility of any identified gene combinations.

CliniQuantum intends to continue advancing its algorithms toward the analysis of increasingly complex multifeature configurations and larger biomedical datasets, while progressing its development pathway from simulation and validation toward execution on quantum computing hardware.

About CliniQuantum

CliniQuantum is engaged in the development of a platform that applies quantum simulation and quantum Monte Carlo methods to clinical trial data analysis, with the objective of improving the precision of clinical trial outcomes through the identification of patient subpopulations that respond to investigational therapies. CliniQuantum is at an early stage of development and has not generated any revenue to date.

About Neurothera Labs Inc.

Neurothera Labs is a clinical-stage pharmaceutical company focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations.

We seek Safe Harbor.